Advertisement

PharmacoEconomics

, Volume 37, Issue 4, pp 621–623 | Cite as

The Inclusion of Spillover Effects in Economic Evaluation: A Public Health Economics Perspective

  • Rhiannon Tudor EdwardsEmail author
Letter to the Editor

Dear Editor,

Reading the debate between Brouwer and McCabe about whether spillover costs and outcomes should be included in economic evaluation [1, 2], it strikes me that what is never discussed is the ‘opportunity cost’ of ‘not’ addressing demand side factors in health economics. The estimates of the cost of mental health problems among the UK workforce range from £74 billion to £99 billion per year to the economy, which is equivalent to four-fifths of the whole annual budget of the National Health Service (NHS) in England [3]. It costs one and a half times more to treat the chronic health problems of a person who also has untreated depression than a patient without depression [4].

Sometimes it is helpful to go back to basics. Many students of health economics will recognise the Williams plumbing diagram [ 5] reproduced in Fig.  1. The debate between Brouwer and McCabe is taking place in boxes D (supply of healthcare) and E (micro-economic evaluation at treatment level). As a Public...

Notes

Compliance with ethical standards

Funding

No funding was received in relation to the writing of this letter.

Conflict of interest

Rhiannon Tudor Edwards has no conflicts of interest to declare.

References

  1. 1.
    Brouwer WB. The inclusion of spillover effects in economic evaluations: not an optional extra. PharmacoEconomics. 2018.  https://doi.org/10.1007/s40273-018-0730-6 (Epub 17 Oct 2018).Google Scholar
  2. 2.
    McCabe C. Expanding the scope of costs and benefits for economic evaluations in health: some words of caution. PharmacoEconomics. 2018.  https://doi.org/10.1007/s40273-018-0729-z (Epub 17 Oct 2018).Google Scholar
  3. 3.
    Department for Work and Pensions. Thriving at work: the Stevenson/Farmer review of mental health and employers. 2018. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/658145/thriving-at-work-stevenson-farmer-review.pdf. Accessed 7 Nov 2018.
  4. 4.
    Layard R, Clark DM. Thrive: the power of psychological therapy. London: Penguin; 2015.CrossRefGoogle Scholar
  5. 5.
    Williams A. Health economics: the cheerful face of the dismal science? In: Williams A, editor. Health and economics. British Association for the Advancement of Science. London: Palgrave Macmillan; 1987.Google Scholar
  6. 6.
    Owen L, Morgan A, Fischer A, Ellis S, Hoy A, Kelly MP. The cost-effectiveness of public health interventions. J Public Health. 2011;34(1):37–45.CrossRefGoogle Scholar
  7. 7.
    Edwards RT. Paradigms and research programmes: is it time to move from health care economics to health economics? Health Econ. 2001;10(7):635–49.CrossRefGoogle Scholar
  8. 8.
    Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093–103.CrossRefGoogle Scholar
  9. 9.
    NHS England. 12 million people to benefit from better joined up NHS and social care work. 2018. https://www.england.nhs.uk/2018/05/12-million-people-to-benefit-from-better-joined-up-nhs-and-social-care-work/. Accessed 22 Oct 2018.
  10. 10.
    Marmot M, Allen J, Goldblatt P, Boyce T, McNeish D, Grady M. Fair society, healthy lives: the marmot review. 2010. http://www.instituteofhealthequity.org/resources-reports/fair-society-healthy-lives-the-marmot-review. Accessed 7 Nov 2018.
  11. 11.
    Edwards RT, McIntosh E. Applied health economics for public health practice and research. Oxford: Oxford University Press; 2019 (in press).Google Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.Centre for Health Economics and Medicines Evaluation (CHEME)Bangor UniversityBangorUK

Personalised recommendations